Cargando…

Lung squamous cell carcinoma exhibits a targetable glucose dependency unique among non-small cell lung cancers

Cancer cells consume high amounts of glucose for their cellular bioenergetic and anabolic requirements, relying on glucose to fuel their growth. We recently reported that lung squamous cell carcinoma, a major subtype of non-small cell lung cancer (NSCLC), exhibits remarkably elevated glucose transpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goodwin, Justin, Neugent, Michael L., Kim, Jung-Whan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644473/ https://www.ncbi.nlm.nih.gov/pubmed/29057314 http://dx.doi.org/10.1080/23723556.2017.1364211

Ejemplares similares

The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
por: Goodwin, Justin, et al.
Publicado: (2017)

Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer
por: Mäkinen, Netta, et al.
Publicado: (2023)

Minimalistic immunohistochemical approach to non-small cell carcinoma of the lung in small biopsies in the context of the 2015 WHO Classification of Lung Cancer
por: Siddaraju, Neelaiah
Publicado: (2017)

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

New first-line treatment strategies for advanced lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

A Unique Case of Atrial Fibrillation Secondary to Squamous Cell Lung Carcinoma
por: Malik, Mohammad J, et al.
Publicado: (2023)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Unique Role for a DNA Methyltransferase Isoform in Lung Cancer
por: Duymich, Christopher E., et al.
Publicado: (2015)

A unique metabolic dependency for liver cancer stem cells
por: Katt, William P.
Publicado: (2018)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

New potential targeted strategies in small cell lung cancer
por: de Toro, María, et al.
Publicado: (2023)

Commentary: A novel approach for localization of small lung nodules
por: Brandt, Whitney S., et al.
Publicado: (2020)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma
por: Cai, Xiuyu, et al.
Publicado: (2020)

Squamous Cell Carcinoma of the Lung
por: Suarez, Eric, et al.
Publicado: (2017)

Tumor Vascularity and Glucose Metabolism Correlated in Adenocarcinoma, but Not in Squamous Cell Carcinoma of the Lung
por: Zhang, Jiuquan, et al.
Publicado: (2014)

Squamous cell carcinoma mimics small cell carcinoma of the lung: a case report
por: Kmeid, Michael, et al.
Publicado: (2020)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

A New Perspective on the Heterogeneity of Cancer Glycolysis
por: Neugent, Michael L., et al.
Publicado: (2018)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Commentary: Evolution of pediatric living-donor lung transplant: Adaptation to unique environment
por: Adachi, Iki, et al.
Publicado: (2020)

Commentary: Squamous cell carcinoma of the esophagus: Another target for checkpoint inhibition
por: Whyte, Richard I.
Publicado: (2022)

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
por: Froudarakis, Marios E, et al.
Publicado: (2010)

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
por: Ho, Hsiang-Ling, et al.
Publicado: (2019)

Isolated Renal Metastasis from Primary Lung Squamous Cell Carcinoma with Synchronous Small Cell Lung Cancer
por: Numan, Laith, et al.
Publicado: (2019)

CUL4 E3 ligase regulates the proliferation and apoptosis of lung squamous cell carcinoma and small cell lung carcinoma
por: Li, Ting, et al.
Publicado: (2020)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer
por: Li, Piaopiao, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Expression Profiles and Clinicopathologic Features in Early Resected Non-small-cell Lung Cancer()
por: Rosell, Rafael
Publicado: (2014)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Alterations in serum protein glycopatterns related to small cell lung cancer, adenocarcinoma and squamous carcinoma of the lung
por: Jia, Liyuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m4adohb0umdajg3u904pl2sqvp